Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Verneris

Showing results (171-180 of 180) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 180 results.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
The New England Journal of Medicine|February 1, 2018
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaShannon L Maude, Theodore W Laetsch, Jochen Buechner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
Frontiers in Immunology|April 15, 2021
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell PhenotypesJuan A Marín-Jiménez, Anna Capasso, Matthew S Lewis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 26, 2016
Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell TransplantationKaren Ballen, Kwang Woo Ahn, Min Chen, et al.
Blood Advances|August 19, 2025
International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AMLSwati Naik, Richard Aplenc, Susanne H C Baumeister, et al.
Blood Advances|July 21, 2025
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecelSwati Naik, Subodh Selukar, Aimee C Talleur, et al.
Transplantation and Cellular Therapy|November 14, 2025
Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter StudyZahra Hudda, Aaron Webster, Eric Anderson, et al.
Nature Communications|April 18, 2024
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessmentMichael D Keller, Patrick J Hanley, Yueh-Yun Chi, et al.
Transplantation and Cellular Therapy|July 26, 2021
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Pageof 18

Showing results (171-180 of 180) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 180 results.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
The New England Journal of Medicine|February 1, 2018
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaShannon L Maude, Theodore W Laetsch, Jochen Buechner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
Frontiers in Immunology|April 15, 2021
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell PhenotypesJuan A Marín-Jiménez, Anna Capasso, Matthew S Lewis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 26, 2016
Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell TransplantationKaren Ballen, Kwang Woo Ahn, Min Chen, et al.
Blood Advances|August 19, 2025
International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AMLSwati Naik, Richard Aplenc, Susanne H C Baumeister, et al.
Blood Advances|July 21, 2025
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecelSwati Naik, Subodh Selukar, Aimee C Talleur, et al.
Transplantation and Cellular Therapy|November 14, 2025
Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter StudyZahra Hudda, Aaron Webster, Eric Anderson, et al.
Nature Communications|April 18, 2024
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessmentMichael D Keller, Patrick J Hanley, Yueh-Yun Chi, et al.
Transplantation and Cellular Therapy|July 26, 2021
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Pageof 18